Last updated September 12, 2026
Key finding
Median UACR decreased from 574.6 to 373.5 mg/g with finerenone.
The study examined the effects of finerenone on urinary albumin-to-creatinine ratio in adults with type 1 diabetes and chronic kidney disease, showing a significant reduction in UACR compared to placebo.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study examined the effects of finerenone on urinary albumin-to-creatinine ratio in adults with type 1 diabetes and chronic kidney disease, showing a significant reduction in UACR compared to placebo.
This finding is clinically significant as it suggests that finerenone may be an effective treatment option for managing kidney disease in patients with type 1 diabetes. By reducing UACR, finerenone could help slow the progression of kidney damage, which is a common complication in diabetes. This could lead to improved long-term health outcomes for these patients.
The study's findings may not be generalizable to all populations with diabetes. The long-term effects of finerenone were not assessed beyond the study duration. Potential unmeasured confounders could influence the outcomes.
Published in
Publication details and source links for this paper.
Jelle MB, Hiddo JH, Andreas LB, et al. Finerenone Reduces Urinary Albumin-to-Creatinine Ratio in Adults with Type 1 Diabetes and CKD. Diabetes Care. 2026;49(8):1434-1441. doi:10.2337/dc26-0882
Finerenone reduced UACR from 574.6 to 373.5 mg/g, a decrease of -201.1 mg/g (P = 0.0001).
Placebo group showed a smaller decrease in UACR from 506.4 to 475.6 mg/g.
HbA1c levels remained unchanged in both finerenone and placebo groups.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Gastrointestinal disorders incidence, HbA1c, Incidence of hyperkalemia, and 2 more.
This study contributes evidence to
Primary intervention
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
5
Evidence pairs
742
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_intervention_and_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Gastrointestinal disorders incidence
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Gastrointestinal disorders incidence
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → HbA1c
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → HbA1c
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of hyperkalemia
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of hyperkalemia
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Serious adverse events
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Serious adverse events
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Urinary albumin-to-creatinine ratio
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Urinary albumin-to-creatinine ratio
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Incidence of hyperkalemia.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies on Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Contributes to Finerenone (nonsteroidal mineralocorticoid receptor antagonist) evidence base.
All studies measuring Incidence of hyperkalemia
Measures Incidence of hyperkalemia as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
3 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
Current evidence does not show a clear reduction in incidence of hyperkalemia with Finerenone (nonsteroidal mineralocorticoid receptor antagonist).
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Incidence of hyperkalemia
EvidenceScore™ Strong | EvidenceScore™ 77.1 | neutral | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve urinary albumin-to-creatinine ratio.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Urinary albumin-to-creatinine ratio
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear reduction in gastrointestinal disorders incidence with Finerenone (nonsteroidal mineralocorticoid receptor antagonist).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Gastrointestinal disorders incidence
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Finerenone (nonsteroidal mineralocorticoid receptor antagonist) for HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
